Shares of Tyson Foods Inc. (NYSE: TSN) were down 1% on Friday. The stock has dropped 27% over the past 12 months. The company is scheduled to report its first quarter 2023 earnings results on Monday, February 6. Here’s a look at what to expect from the report:
Revenue
Analysts estimate sales of $13.5 billion for Tyson Foods in Q1 2023. This compares to sales of $12.9 billion reported in Q1 2022. In the fourth quarter of 2022, Tyson reported sales of $13.7 billion, which was up 7% year-over-year, benefitting from price increases and volume growth.
Profits
Analysts are projecting EPS of $1.36 for Q1 2023. This compares to adjusted EPS of $2.87 reported in the first quarter of 2022. For the fourth quarter of 2022, Tyson reported adjusted EPS of $1.63, which was down 29% YoY.
Points to note
Even in the current inflationary environment, demand for protein has remained relatively steady and Tyson has benefited from this trend thanks to its diverse portfolio of products. In Q4, total company volume increased 2%. Chicken and beef volumes rose helped by higher domestic production and head throughput, but pork volumes declined due to limited hog supply and lower export demand. Volumes in the international segment rose the highest at 7% due to investments in capacity and brands.
Tyson expects chicken and beef volumes to remain steady in 2023 but pork volumes are likely to be affected by the same challenges it saw last year. In Q4, volumes in Prepared Foods gained from brand investments and market share growth. Volumes are expected to grow in the coming year as well helped by these brand investments and a pickup in the foodservice business.
Tyson is seeing strong growth in its retail and foodservice channels as well. Its core business lines grew volume share by 2.6 points in Q4 and it gained share in the majority of its core categories, including frozen protein breakfast, smoked sausage and corn dogs.
The company is taking several measures to drive volume growth and margin improvement and to generate cost savings. It is also implementing various degrees of pricing in its key categories to tackle inflationary pressures. These efforts are likely to have benefited results in the first quarter.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on